Thirteen blood samples of thallium-poisoned people were cytogenetically investigated. The thallium concentration in blood varied from 25 to 2700 microg/L. The mean frequency of chromosomal aberrations in the poisoned group significantly exceeded our control level (7.08+/--2.19% and 2.03+/--0.25, p<.001). The rate of single fragments was significantly higher in poisoned group (7.77+/-2.68% and 1.59+/-0.23%, p<.001) while the frequencies of other types of chromosomal aberrations were similar in both groups. It is possible that thallium is an S-dependent clastogenic agent because the majority of the structural aberrations are of the chromatid type. Irrespective of mechanisms, damage to genetic material was revealed in thallium-poisoned people.
In Ukraine more than 13,000 lower limb amputations are performed per year, of which about 8,000 are due to vascular lesions, and more than 3,000 are associated with diabetes mellitus (DM). The effectiveness of photodynamic therapy (PDT) in group 1 was assessed by the VCSS-1 and VCSS-2 scales. At baseline, the total score of clinical severity of CVI was 20.9 points, and two weeks later – 15.71 points, which shows an improvement by 24.83% (p≤0.05). The effectiveness of PDT in group 2 was assessed by the S(AD) SAD-1 scales at baseline and S(AD) SAD-2 at 2 weeks. The overall score on the scale S(AD) SAD-1 was 13.91 points, two weeks later it improved by 11.65% (12.29 points), which shows a much slower rate of normalization of the clinical picture in patients with diabetes compared with CVI. The effectiveness of plasma therapy in group 1 was assessed by the VCSS-1 and VCSS-3 scales. The total score of clinical severity of CVI after 6 weeks of treatment was 9.72 points, indicating an improvement in clinical status by 53.49% from baseline (20.9 points) (p≤0.05). In group 2, the evaluation of the effectiveness of plasma therapy was based on a comparison of the scales S(AD) SAD-1 and S(AD) SAD-3. The overall score of clinical severity at 6 weeks was 6.39 points, indicating an improvement by 54.06% from baseline (13.91 points). Analysis of the ulcer healing dynamics in group 1 revealed 0 points (no active ulcers) in 87.5% of patients (28 patients), while in the remaining 4 patients the size of active ulcers was 1 point. In group 2, the dynamics of the area reduction showed slower results: in 74.2% of patients the TU area was 2 points, 0 points were achieved in 12.9% patients, in the remaining patients (12.9%) – 4 points. Due to using of combined scheme of basic therapy, supplemented with PDT at the initial stage and plasma therapy in the granulation phase, it was possible to improve the dynamics of the rate of healing of TU and reduce the duration of treatment.
The study of comorbid pathologies that influence the severity of the disease and impair the effectiveness of treatment is carried out to optimize the treatment of the main disease. Materials and methods. The total of 132 medical students was divided into two groups: the 1st group: 56 students who didn`t have acne elements, the 2nd group: 76 students with mild acne vulgaris. At the baseline and after 12 months epithelial tape-test was performed to define Demodex mites presence. The theory of chances was used to assess the impact of acne on the occurrence of Demodex mites. Results. The presence of Demodex mites was observed in 3.57% of students in the 1st group and in 21.05% of students in the 2nd group on repeated tape-test. The probability value (P) among students of the 1st group was P1 = 0.037; among students of the 2nd group – P2 = 0.266. The odds (O) indicator in the 1st group of students without acne elements was O1 = 0.04, in the 2nd group diagnosed with acne – O2 = 0.21. The odds ratio (OR) value in the case/control groups was 7.20. Confidence intervals (95% CI) – (1.582, 32.765): the lower limit of the confidence interval (2.019, + ∞); the upper limit of the confidence interval (-∞, 25680). The significance test p-value was 0.00533. Conclusion. Acne vulgaris is one of the aggravating factor that increases the risk of Demodex mites.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.